Page 11 - Asahi Kasei Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Glycomine Raises $68M in Series B Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Glycomine Raises $35 Million to Advance Novel Treatment for Rare Glycosylation Disease
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito life or LinkedIn.
About Pulmocide
Pulmocide Ltd (www.pulmocide.com) is a late-stage biopharmaceutical company developing novel therapies for patients suffering from serious acute and chronic respiratory diseases. Pulmocide’s lead product is PC945, a novel antifungal specifically designed for inhaled use to maximize the amount of drug in the lung